Â鶹´«Ã½É«ÇéƬ

Cardiovascular diseases are among the leading causes of death globally, taking an estimated . An important risk factor of heart disease is an unhealthy diet leading to overweight and obesity, high blood pressure and increased levels of glucose and lipids in blood. Drugs that help manage body weight have clinical value but do not help prevent premature deaths. Hence, scientists seek ways to identify and treat individuals at higher risk of heart disease.

/iStock

Low-density lipoprotein particles transport cholesterol, phospholipids, triglycerides and certain vitamins in blood plasma. A single LDL particle contains 3,000 to 6,000 fat molecules and a single apolipoprotein B molecule, a large protein (blue), building the surface with phospholipids and cholesterol molecules (orange).

Increased levels of triglycerides and small low-density lipoproteins, or LDL, and low level of high-density lipoproteins, or HDL are markers of atherogenic dyslipidemia, a metabolic condition that builds plaques in the arteries, leading to heart diseases. Previously, cross-sectional studies have shown a correlation between high triglyceride levels and soluble LDL receptor, or sLDLR.

Ronald Krauss and his group at the University of California, San Francisco in collaboration with Christopher Gardner’s team in Stanford University recently showed dynamic changes in lipids and lipoproteins in conjunction with sLDLR; was published in the Journal of Lipid Research.

Krauss is interested in understanding the mechanisms regulating plasma lipoprotein metabolism that may impact cardiovascular disease risk and discovering sLDLR as an important component that impacts it. The Krauss lab uses ion mobility analysis to subdivide fractions of various densities of lipoproteins into narrow intervals of their respective subclasses. His team used this technique to study the correlation between lipoprotein particles and cardiometabolic risk, a lipid measure of heart disease risk.

Gardner provided samples from Diet Intervention Examining the Factors Interacting with Treatment Success, or DIETFITS, a study in which people were given either a healthy low-fat or low-carbohydrate diet to determine how lipid and lipoprotein fractions influence cardiometabolic risk. The researchers investigated the cross-sectional and longitudinal relationship of lipids, lipoproteins related to the level of sLDLR and triglyceride with a baseline of six months.

According to Krauss, using principal component analysis, his team showed that the level of sLDLR is tightly regulated to these other lipid measurements. The study population was limited, so this study must be replicated to make generalizations about the conclusions.

It has already been shown that he protease, membrane type 1–matrix metalloproteinase, or MT1-MMP, cleaves the ligand binding domain of sLDLR capable of binding to very low-density lipoprotein, or VLDL, and LDL particle and increases the level of sLDLR in plasma.

“The work is clinically and scientifically important for developing new therapeutic approaches to either target the protease and/or other mechanisms to inhibit the cleaving of LDLR,” Krauss said. “As the free domain of LDLR circulating in plasma acquires new function by binding to VLDL, mechanisms to directly stop the association of LDLR with VLDL could also be potential measurement to lower the atherogenic dyslipidemia.”

Krauss said the study opens new avenues to explore “how the soluble LDLR achieves this new feature by unknown conformational changes.”

“MT1-MMP is thought to be activated by unknown inflammatory signaling pathways,” he said, “which also needs further investigation along with its mode of interaction with sLDLR.”